DexCom, Inc. $DXCM Shares Sold by Pitcairn Co.

Pitcairn Co. cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 42.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 10,399 shares of the medical device company’s stock after selling 7,539 shares during the quarter. Pitcairn Co.’s holdings in DexCom were worth $700,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of DXCM. Andra AP fonden purchased a new position in shares of DexCom during the second quarter worth $26,000. Twin Peaks Wealth Advisors LLC acquired a new position in DexCom during the second quarter valued at $26,000. SJS Investment Consulting Inc. boosted its holdings in DexCom by 4,800.0% in the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 384 shares during the last quarter. Financial Consulate Inc. purchased a new stake in DexCom in the third quarter valued at $29,000. Finally, Sound Income Strategies LLC grew its position in DexCom by 83.8% during the 3rd quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after purchasing an additional 285 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on DXCM shares. Leerink Partners reissued an “outperform” rating and issued a $92.00 price objective on shares of DexCom in a report on Tuesday, December 16th. Barclays reaffirmed an “underweight” rating and set a $72.00 target price (up from $71.00) on shares of DexCom in a report on Friday, February 13th. Evercore initiated coverage on DexCom in a research report on Tuesday, November 25th. They set an “in-line” rating and a $68.00 price target for the company. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 16th. Finally, Canaccord Genuity Group set a $95.00 price objective on DexCom and gave the stock a “buy” rating in a research report on Friday, February 13th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average price target of $85.18.

DexCom Trading Down 3.7%

DXCM stock opened at $68.10 on Friday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The firm has a market cap of $26.21 billion, a P/E ratio of 32.43, a PEG ratio of 1.32 and a beta of 1.48. The company’s 50-day simple moving average is $70.69 and its 200-day simple moving average is $68.84.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. The firm had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.DexCom’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.45 EPS. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.